Well there is more to it. A project they've been working on with a large pharma over the course of 12 months (unbeknownst to all of us), is moving into its clinical trial phase (which will give us revenue albeit not much), and depending on how that goes it may eventually lead to some commercial application (where you'd assume they'd continue licensing our technology). Just because this won't materialise much in the short term doesn't make it insignificant it's quite an interesting development IMO. Also even in the short term having us associated with them and our technology being utilised in their clinical study is a positive in itself.
But whether the market sees this as something that will develop into some commercial application and that's why the change in SP I don't know. Although I'd suspect it to be more likely just traders rather than a serious rerate.
RAP Price at posting:
12.5¢ Sentiment: Buy Disclosure: Held
